SMA Newsroom

Sep 4, 2020

AveXis' name is changed to Novartis Gene Therapies EU Ltd

AveXis, which has been part of Novartis since 2018, is becoming Novartis Gene Therapies, EU Ltd. (Novartis Gene Therapies) a new unit dedicated to developing innovative AAV-based gene therapies.

While the name of the organisation changes, the commitment to patients and their families remains steadfast. Novartis Gene Therapies will continue to focus on the research, development, manufacturing and commercialisation of innovative gene therapies targeting rare and devastating diseases.